Organic Chemistry TRIZ Cases

Selective STING antagonists reduce inflammatory cytokine production in human and murine cells while addressing off-target inhibition.

These sulfonamide derivatives block IgE binding to FcεRI, helping prevent mast-cell activation and allergic responses.

Variability and instability in Sceletium alkaloids can limit therapy; modified mesembrine analogues preserve PDE4 and SERT inhibition while reducing emesis.

Composite lipid nanoparticles combine cationic, neutral, cholesterol, and polymer-conjugated lipids to protect nucleic acids from plasma nucleases.

Selective ATP-hydrolysis inhibition targets glycolytic cancer cells while sparing normal-cell function and addressing oligomycin’s narrow therapeutic window.

Ionizable amino and PEG-lipids form composite nanoparticles that balance encapsulation, cellular uptake, and endosomal release for gene editing.

A controlled dihedral angle extends π-conjugation while restricting molecular vibration, enabling long-wavelength infrared emission with high quantum yield.

Apple juice supplies a biodegradable organic catalyst for pyrrole formation under mild conditions, avoiding toxic metals and harsh reagents.

Poor tumor penetration and short half-life limit peptide proteasome inhibitors; RPN13-targeting spirocyclic compounds offer oral bioavailability.

These compounds target HER2 exon 20 mutations while limiting wild-type EGFR activity, addressing dose-limiting toxicity in NSCLC.

Mpro-targeting compounds address COVID-19 treatment safety concerns with potent inhibition, plasma stability, and potential oral dosing.

Modified inhibitor structures target CDK2, CDK4, and CDK6 while improving selectivity and enabling brain penetration for cancer treatment.

IRE1 inhibitors block cancer-cell ER stress adaptation, targeting a survival mechanism in solid and hematologic cancers.

Aqueous acid, surfactant, and optional alkali washes simplify crude (−)-Ambrox purification without ethanol or mother liquor reworking.

Mineral-acid precipitation and organic-base treatment cut staurosporine impurities by up to 100% and achieve purity above 98% without chromatography.

Substituted quinazolinone compounds target H-Y-Φ PARPs to improve selectivity while preserving inhibition activity for cancer and asthma treatment.

See how substituted 1,3,5-triazine compounds target CX3CR1 to support orally active treatment approaches for heart failure.

Ring-opening and bioisosteric changes target PI3Kα with aminoquinazolinone derivatives, improving solubility and limiting toxic side effects.

A dihydroquinoline core with varied aryl and heteroaryl substituents targets fade rate, optical density, sensitivity, and absorption ratio.

Replacing chromatography with staged filtration and extraction helps produce ozanimod at industrial scale while maintaining purity and yield.

Three-dimensional rigid groups help prevent crystallization in electron transport materials, supporting high luminous efficiency and longer OLED life.

Replacing volatile solvents with carrier oil and catalysis addresses safety and cost barriers while producing high-purity Δ8-THC.

Layer-specific HOMO alignment smooths carrier transport in organic EL devices, lowering driving voltage and supporting efficient, reliable emission.

Low-purity Azure C has poor solubility and lot variation; amino protection enables organic extraction and deprotection for higher-purity biosensor reagent.

Formula (1) matrix compounds combine with hole-transporting compounds to extend phosphorescent OLED lifetime at low emitter concentrations.

Chiral tartaric acid salts separate the desired (S)-Finerenone intermediate by crystallization, improving purity and yield for scale-up.

A polymer-based chemically amplified resist combines acid control with etch resistance and solvent solubility for stable small-pattern formation.

Replacing glycidyl groups with thioepoxy groups raises refractive-index potential while retained (meth)allyl groups support polymerization.

Solution-deposited Pb-free double perovskites address costly, toxic, unstable SWIR materials with simpler processing and improved stability.

Existing TRPA1 treatments are inadequate across many conditions; pyridone compounds broaden inhibition for pain, skin, respiratory, and fibrotic disorders.

Formula 1 amine compounds improve hole transport and electron recombination to address low efficiency and short service life in organic electroluminescent elements.

Selective α7 nAChR agonists suppress cough and reduce inflammation without significant cardiovascular or skeletal-muscle side effects.

Selective ATM and DNA-PK inhibitors sensitize tumor cells to radiation while checkpoint blockade strengthens the anti-cancer immune response.

DPP-based photoactive compounds enable vacuum-deposited transparent or opaque photovoltaics for scalable manufacturing and visible-light transparency.

Diels-Alder or aromatic disulfide bonds let glycidyl ether cured products be repaired and remolded while maintaining mechanical strength.

New ring and substituent configurations in GPR132 modulators broaden therapeutic coverage for atherosclerosis, colorectal inflammation, leukemia, and transplantation.

Specific mono- and difunctional (meth)acrylic thioester monomers balance high refractive index and low viscosity while limiting chipping and turbidity.

A decomposition-type infrared absorber in the image-recording layer supports on-press development while improving printing durability.

Molecular substituents tune CDK2/4/6 inhibitor selectivity against altered tumor kinase regulation, with brain penetration across cancers.

This adhesive composition uses CH-π interaction and photopolymerized coating to bond cycloolefin resin without UV-ozone treatment.

A Formula (1) compound creates visible color for on-press development, reducing waste liquids while preserving printing durability.

Immobilized AOL lipase produces furfuryl esters while limiting alcohol polymerization.

Indenocarbazole compounds improve OLED hole transport, electron blocking, and thermal stability.

Structural tuning improves analogue solubility, stability, uptake, and assay compatibility.

Controlled polymerization integrates aromatic components into a moldable polycarbonate resin for clear, heat-stable optical articles.

This case uses substituted sulforaphane compounds to inhibit SRF/MRTF signaling, reduce fibrosis markers, and limit side effects.

A temperature formula for fresh catalyst beds limits discharge heat while sustaining alkylene oxide conversion and selectivity.

Benzo 2-azaspiro[4.4]nonanes target S1PR1 selectivity while limiting side effects.

This case uses CYP1B1 hydroxylation to release an effector molecule in cancer cells, limiting toxicity to normal tissues.

Non-peptide pyrimidinediones address peptide drug limits with oral GnRH antagonism.